

Patients with newly diagnosed or recurrent MBC

Biopsy of metastatic lesion to confirm diagnosis

Reassess biomarkers ER, PgR, HER2 [ESCAT I-A]<sup>a,b</sup>

Patients with TNBC tumours

All patients

Patients with ER+/HER2- tumours

PD-L1 by IHC [ESCAT I-A]<sup>b</sup>  
*gBRCAm* [ESCAT I-A] (*PALB2* assessment optional [ESCAT II-A])<sup>b</sup>

*PIK3CA* mutation status [ESCAT I-A]<sup>b</sup>  
*gBRCAm* [ESCAT I-A] (*PALB2* assessment optional [ESCAT II-A])<sup>b</sup>

Assessments only where corresponding therapies are available: MSI [ESCAT I-C], TMB, *NTRK* [ESCAT I-C]<sup>b</sup>

Optional assessments with potential to guide treatment: *ESR1* (in ER+/HER2- tumours if further AI-based therapy is considered) [ESCAT II-A]<sup>b</sup>, somatic *BRCA* mutations [ESCAT II-A]<sup>b</sup>, HER2-low status by IHC [ESCAT II-B]<sup>b</sup>

Staging: history and physical examination, haematology, biochemistry, tumour markers, CT of the chest and abdomen and bone scintigraphy (or PET-CT), brain imaging (symptomatic patients or according to subtype if the presence of CNS metastases will alter the choice of therapy)